Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | TRPV1 | Q8NER1 | 10/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.59 |
| ▸ | NAMPT | P43490 | 1/20 | 0.57 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13762079 | 0.90 | NPC1 (0.77) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL13863924 | 0.87 | MEN1 (0.73) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL7101847 | 0.85 | PABPC1 (0.79) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL3890282 | 0.84 | MEN1 (1.00) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL13998319 | 0.84 | MEN1 (0.76) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL13863923 | 0.84 | MEN1 (0.71) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL4428905 | 0.83 | TRPV1 (0.76) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL3878438 | 0.83 | MEN1 (0.74) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL4433847 | 0.82 | MEN1 (0.73) | MEN1KMT2ATRPV1NPC1RAB9A | |
| SCHEMBL13675738 | 0.81 | TRPV1 (1.00) | MEN1KMT2ATRPV1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| US-7538121-B2 | Vanilloid receptor modulators | GLAXO GROUP LIMITED (GB) | 2009-05-26 | — | — | US | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| EP-2033953-A1 | Vanilloid receptor modulators | Glaxo Group Limited (GB) | 2009-03-11 | — | — | EP | disclosed |
| US-20060142333-A1 | Vanilloid receptor modulators | MACDONALD GREGOR J | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142333-A1 | Vanilloid receptor modulators | TRPV1, NPSR1, TRPV3 | MEN1 3527/4885KMT2A 3992/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.